All In Biotech

Drug Trial Radar · NCT04496349

A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With R/R T-PLL and NHL

A Phase IIa Study Evaluating the Pharmacokinetics, Safety and Efficacy of APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With Relapsed/Refractory T-Cell Prolymphocytic Leukemia (R/R T-PLL) or Non-Hodgkin's Lymphoma (NHL).

Last checked: Nov 19, 2026Latest source record: Nov 4, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

78

Planned (sponsor's estimate)

Start

Jul 12, 2021

Primary completion

May 31, 2026

Study completion May 31, 2027

Sponsor

Lead sponsor
Ascentage Pharma Group Inc.Industry
Sponsor type
Industry
First posted
Aug 3, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this study is to evaluate the pharmacokinetics (PK), safety, and efficacy of APG-115 as a single agent or in combination with APG-2575 in patients with T-PLL and NHL.

Conditions

  • T-Prolymphocytic Leukemia
  • Non-Hodgkins Lymphoma

Interventions

  • APG-115Drug

    QOD, 2 weeks on, 1 week off, in repeated 21-day cycles

  • APG-2575Drug

    APG-2575 given orally each day in cycle, in repeated 21-day cycles

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum tolerated dose of APG-115Time frame: 21 days
  2. Maximum tolerated dose of APG-115+APG-2575Time frame: 21 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • MD Anderson

    Houston, Texas · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.